Compare SANA & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SANA | THQ |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.5M | 784.0M |
| IPO Year | 2021 | N/A |
| Metric | SANA | THQ |
|---|---|---|
| Price | $2.01 | $19.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $8.43 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 116.2K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | ★ 17.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $16.28 |
| 52 Week High | $5.49 | $20.39 |
| Indicator | SANA | THQ |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 56.39 |
| Support Level | N/A | $18.83 |
| Resistance Level | $3.41 | $19.41 |
| Average True Range (ATR) | 0.19 | 0.39 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 15.96 | 64.00 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.